Coherus Oncology (CHRS) closed at $0.48 on November 17, 2026, down 5.4% from the previous close, on volume of 3,246,478 shares (30-day average 2,142,813).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
J.P. Morgan Remains a Hold on Coherus Biosciences (CHRS)
TipRanks (Wed, 18-Nov 1:45 AM ET)
Globe Newswire (Mon, 9-Nov 4:06 PM ET)
Globe Newswire (Wed, 28-Oct 4:05 PM ET)
Coherus to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Oct 9:30 AM ET)
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 26-Oct 9:30 AM ET)
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Globe Newswire (Wed, 14-Oct 4:30 PM ET)
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Globe Newswire (Wed, 23-Sep 9:30 AM ET)
Market Chameleon (Tue, 18-Aug 7:44 AM ET)
Market Chameleon (Mon, 5-Jan 6:57 AM ET)
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Coherus Oncology trades on the NASDAQ stock market under the symbol CHRS.
As of November 18, 2026, CHRS stock price declined to $0.41 with 1,762,570 million shares trading.
CHRS has a beta of 0.63, meaning it tends to be less sensitive to market movements. CHRS has a correlation of 0.01 to the broad based SPY ETF.
CHRS has a market cap of $63.35 million. This is considered a Micro Cap stock.
Last quarter Coherus Oncology reported $14 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.01.
In the last 3 years, CHRS traded as high as $3.70 and as low as $.41.
The top ETF exchange traded funds that CHRS belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IWN.
CHRS has underperformed the market in the last year with a price return of -63.7% while the SPY ETF gained +11.2%. CHRS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.3% and -49.1%, respectively, while the SPY returned -4.9% and -2.9%, respectively.
CHRS support price is $.45 and resistance is $.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CHRS shares will trade within this expected range on the day.